• 11/26/2024

Novartis’s Sandoz Sets Out Post-Spinoff Growth Plan

Wall Street Journal

Novartis’s generics unit Sandoz forecast product pipeline net sales of $3 billion over the next five years and a core earnings margin of 18%-19% this year, lower than previously forecast due to inflation and costs.

https://www.wsj.com/articles/novartiss-sandoz-sets-out-growth-plan-following-proposed-spinoff-9c1058ac